SpyGlass Pharma, Inc.
corporate_fare Company Profile
SpyGlass Pharma, Inc. (NASDAQ:SGP) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 32 items for SGP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for SGP spans 10-Q, 8-K, 10-K, SCHEDULE 13D.
Recent high-impact activity:
- SpyGlass 10-Q: $57.9M Nine-Month Loss, Material Weakness Persists, $215.8M Cash Through 2028
- Four-Year Glaucoma Implant Data Show 37% IOP Cut, 86% Drop-Free
- SpyGlass Pharma Buys IOL Manufacturer AVS for $13M, Securing Supply for Phase 3 Trials
- SpyGlass Pharma Q2 Loss Widens to $19.9M; Material Weakness Persists, Cash Runway Through 2028
- SpyGlass Pharma Reports Q1 2026 Results, Confirms Cash Runway Through 2028 Post-IPO
Financial Snapshot
Short Interest & Short Volume
12.05 days to coverFINRA reported short interest of 1,160,601 shares in SGP as of the October 30, 2026 settlement, a 5.2% decrease from the prior period — about 12.1 days to cover at its recent average daily volume. On November 20, 2026, 78.1% of SGP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.